Esperion Therapeutics Inc (NASDAQ:ESPR) Director Dov A. Md Goldstein sold 800,000 shares of the stock in a transaction that occurred on Wednesday, March 22nd. The stock was sold at an average price of $41.66, for a total value of $33,328,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.
Esperion Therapeutics Inc (NASDAQ:ESPR) opened at 38.94 on Monday. The firm’s 50-day moving average price is $27.73 and its 200 day moving average price is $16.01. The company’s market capitalization is $878.29 million. Esperion Therapeutics Inc has a one year low of $9.40 and a one year high of $48.21.
Esperion Therapeutics (NASDAQ:ESPR) last posted its quarterly earnings data on Wednesday, February 22nd. The biopharmaceutical company reported ($1.29) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.24) by $0.05. During the same quarter last year, the company earned ($0.58) earnings per share. On average, equities research analysts expect that Esperion Therapeutics Inc will post ($6.04) earnings per share for the current fiscal year.
Several hedge funds have recently modified their holdings of the company. Pentwater Capital Management LP boosted its stake in shares of Esperion Therapeutics by 19.0% in the fourth quarter. Pentwater Capital Management LP now owns 1,828,000 shares of the biopharmaceutical company’s stock worth $22,887,000 after buying an additional 292,000 shares in the last quarter. BB Biotech AG boosted its stake in shares of Esperion Therapeutics by 29.7% in the third quarter. BB Biotech AG now owns 1,308,542 shares of the biopharmaceutical company’s stock worth $18,123,000 after buying an additional 300,000 shares in the last quarter. Senzar Asset Management LLC bought a new stake in shares of Esperion Therapeutics during the fourth quarter worth approximately $4,557,000. JPMorgan Chase & Co. boosted its stake in shares of Esperion Therapeutics by 27.6% in the third quarter. JPMorgan Chase & Co. now owns 181,400 shares of the biopharmaceutical company’s stock worth $2,512,000 after buying an additional 39,239 shares in the last quarter. Finally, J. Goldman & Co LP bought a new stake in shares of Esperion Therapeutics during the fourth quarter worth approximately $2,028,000. 64.65% of the stock is currently owned by hedge funds and other institutional investors.
Several analysts have recently commented on the company. JPMorgan Chase & Co. reissued a “hold” rating and issued a $50.00 price objective (up from $22.00) on shares of Esperion Therapeutics in a research note on Monday, March 20th. Citigroup Inc set a $39.00 target price on Esperion Therapeutics and gave the company a “buy” rating in a report on Monday, March 20th. Royal Bank of Canada reaffirmed a “hold” rating and issued a $45.00 target price on shares of Esperion Therapeutics in a report on Monday, March 20th. Needham & Company LLC upped their target price on Esperion Therapeutics from $25.00 to $58.00 and gave the company a “strong-buy” rating in a report on Monday, March 20th. Finally, Credit Suisse Group AG raised Esperion Therapeutics from an “underperform” rating to a “neutral” rating and set a $29.00 target price for the company in a report on Monday, March 20th. Seven analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $33.39.
About Esperion Therapeutics
Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.
Receive News & Ratings for Esperion Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.